Key Takeaways:
AbbVie Inc. reported its drug ELAHERE (mirvetuximab soravtansine-gynx) demonstrated a 62.7 percent objective response rate in a Phase 2 trial for platinum-sensitive ovarian cancer, according to data presented on April 12, 2026, at the SGO 2026 conference.
The findings from the IMGN853-0420 trial highlighted the drug's potential when combined with carboplatin for patients with high expression of the folate receptor alpha (FRα) protein. The treatment was followed by a continuation of ELAHERE as a standalone therapy.
The study's results showed that in patients whose tumors had ≥50 percent FRα expression, the objective response rate (ORR) of 62.7 percent indicates a meaningful clinical activity. An ORR signifies the proportion of patients whose tumors shrink or disappear after treatment. The safety profile observed in the trial was consistent with previous studies of the drug, with no new safety concerns identified.
These positive late-breaking data suggest a significant opportunity for ELAHERE to move into earlier lines of therapy for ovarian cancer. Currently approved for later-stage, platinum-resistant disease, success in the platinum-sensitive setting would substantially broaden its addressable patient population and future revenue potential for AbbVie.
The results may lead to a positive re-rating of AbbVie's stock and bolster investor confidence in its oncology pipeline. Investors will now look toward future updates on regulatory filings based on these Phase 2 results.
This article is for informational purposes only and does not constitute investment advice.
